Announcement on Subsidiary Companies Participating in the Fourth Batch of National Drug Centralized Procurement to be Bwon
Release time:
2021-05-20
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Lin 2021-003
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Subsidiaries Participating in the Fourth Batch of National Centralized Drug Procurement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
On February 3, 2021 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Group" or "the Company"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), participated in the fourth batch of national centralized drug procurement bids organized by the State Organization for Centralized Drug Procurement and Use Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"), peak Pharmaceutical's Olopatadine Hydrochloride Eye Drops is proposed to win the bid for this centralized procurement. The relevant information is hereby announced as follows:
Basic Situation of 1. Proposed Winning Products
Proposed Winning Products |
Specifications |
Indications |
Proposed Winning Price |
Proposed Winning Quantity |
Provinces |
Olopatadine Hydrochloride Eye Drops |
5ml:5mg (0.1%) |
is suitable for treating signs and symptoms of allergic conjunctivitis |
19.9 yuan/ box |
36.23 box |
Shanghai, Zhejiang, Guangdong, Sichuan, Henan, Liaoning, Hubei, Chongqing, Hunan, Shaanxi, Anhui, Hainan, Xinjiang (including bingtuan), Jiangxi, Qinghai, Tibet |
the bid price and the bid quantity of the above varieties are subject to the final data released by the joint procurement office. According to the relevant winning rules, the bid period for this bid is 1 year.
The impact of 2.'s proposed winning the bid on the company
Jianfeng Pharmaceutical's proposed winning product Olopatadine Hydrochloride Eye Drops obtained the approval of State Drug Administration and issued Drug Registration Approval Document in 4 in 2019 . The market sales volume of was relatively small before , the sales revenue of this product in 2019 and 2020 1-9 September are 5.65 .01 million yuan and 97.74 .03 million yuan respectively, accounting for 2019 annual operating revenue 354 respectively, 753.76 .07 million yuan of 0.0016% and 2020 1-9 March operating income 224,065.44 .15 million yuan of 0.04% .
This centralized procurement is the fourth batch of centralized drug procurement organized by the state. During the procurement cycle, medical institutions will give priority to the drugs selected in this centralized drug procurement and ensure the completion of the agreed procurement volume. The price of the products to be selected this time has decreased to a certain extent compared with the original price. If the company subsequently signs a purchase contract and implements it, it will help expand the sales scale of the product, increase market share, and enhance the company's brand influence, which has a positive impact.3. Risk Alert
At present, the company has signed the "Memorandum of National Drug Centralized Procurement of Selected Varieties" with the Joint Procurement Office. There is still uncertainty about the follow-up matters such as the signing of the purchase agreement for the above products and the impact on the company's future performance. The company will pay close attention to the progress of the matter and timely discharge of information disclosure obligations, so that the majority of investors cautious decision-making, pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
February 5, 2001
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page